Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 1 August 2026.

Announcements

5,263

Total raised

£158B

disclosed amounts

£16.9M

The funding round was led by ABN AMRO Sustainable Impact Fund with backing from a consortium of specialist investors.

"Converge is driving concrete efficiency, smarter optimization, and lower CO₂ emissions in one of the most traditional and high-impact industries. We’re excited to support Raphael, Gideon, and the team on their growth journey as they scale their impact and accelerate the decarbonization of the built environment."
— Gaetano Giuffrè, Investment Manager
Pre-Seed

Zinc VC has led a pre-seed funding round in Native Labs to accelerate platform deployment and feature development.

"We are excited to be partnering with the Native Labs team as they build the critical infrastructure required to accelerate the development and delivery of cell therapies. Their platform is addressing one of the most challenging bottlenecks in the field, enabling more seamless, data-driven communication between developers and manufacturers. In a market that is growing rapidly, and with the potential to transform patient outcomes, Native Labs is not only solving a deeply complex technical challenge but unlocking a massive opportunity for impact across the entire cell and gene therapy ecosystem."
— Emilie Syed
Seed
£3.7M

The seed round was led by Twin Path Ventures to commercialise ultrasonic battery diagnostics.

"This funding represents a significant milestone for Sention as we continue to innovate at the forefront of battery diagnostics. We are grateful to our investors for supporting our mission to enable the electrochemical power revolution by enhancing the performance, quality, and safety of batteries."
— Dan Brett, CEO
Series C
$120M

The financing round was co-led by RA Capital Management and Forbion to support late-stage clinical development.

"We are delighted to secure the investment required to continue to advance inobrodib fully and as effectively as possible. This is a significant raise in a challenging market. Today's announcement is a testament to the data we have in hand, the clear clinical and commercial opportunity inobrodib represents, and the strength of our expanded team."
— Will West, CEO